Maki Gouda

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Topics

Health Insurance

Glycemic Control

Cardiovascular Events

Top Venues

Diabetes, obesity & metabolism

Journal of clinical psychopharmacology

Journal of diabetes investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Maki Gouda, Michikazu Abe, Yumi Watanabe, Takahiro A Kato
Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association. Journal of clinical psychopharmacology 44 (4) (2024)
Hiroaki Iijima, Maki Gouda, Hideaki Hida, Kazumi Mori-Anai, Akiko Takahashi, Ryoichi Minai, Hideki Ninomiya, Yoshiyuki Saito, Atsushi Miyawaki, Jun Wada
Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases. Diabetes, obesity & metabolism 26 (5) (2024)
Hiroaki Iijima, Maki Gouda, Hideaki Hida, Kazumi Mori-Anai, Akiko Takahashi, Ryoichi Minai, Hideki Ninomiya, Yoshiyuki Saito, Atsushi Miyawaki, Jun Wada
Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases. Diabetes, obesity & metabolism 26 (5) (2024)
Maki Gouda, Michikazu Abe, Yumi Watanabe, Takahiro A Kato
Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association. Journal of clinical psychopharmacology (2024)
Hiroaki Iijima, Maki Gouda, Hideaki Hida, Kazumi Mori-Anai, Akiko Takahashi, Ryoichi Minai, Hideki Ninomiya, Yoshiyuki Saito, Atsushi Miyawaki, Jun Wada
Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases. Diabetes, obesity & metabolism (2024)
Maki Gouda, Michikazu Abe, Yumi Watanabe, Takahiro A Kato
Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association. Journal of clinical psychopharmacology 44 (4) (2024)
Maki Gouda, Michikazu Abe, Yumi Watanabe, Takahiro A Kato
Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association. Journal of clinical psychopharmacology 44 (4) (2024)
Maki Gouda, Kenji Arakawa, Masaya Inagaki, Yoshiteru Ushirogawa
Effect of sodium-glucose cotransporter 2 inhibitor medication on new prescriptions of antihypertensives, antigout/antihyperuricemics and antidyslipidemics in Japan: Analysis using the JMDC Claims Database. Journal of diabetes investigation 13 (11) (2022)
Koutaro Yokote, Ryo Suzuki, Maki Gouda, Hiroaki Iijima, Akiko Yamazaki, Masaya Inagaki
Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database. Journal of diabetes investigation 12 (11) (2021)
Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima, Takahiro Matsui, Maki Gouda
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs 79 (7) (2019)
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe, Maki Gouda
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism 19 (6) (2017)